Menu Home

Áåñïëàòíàÿ òåõíè÷åñêàÿ áèáëèîòåêà äëÿ ëþáèòåëåé è ïðîôåññèîíàëîâ Áåñïëàòíàÿ òåõíè÷åñêàÿ áèáëèîòåêà


Àíãëèéñêèé ÿçûê äëÿ ìåäèêîâ. Hematopoietic tissue (êîíñïåêò ëåêöèé)

Êîíñïåêòû ëåêöèé, øïàðãàëêè

Ñïðàâî÷íèê / Êîíñïåêòû ëåêöèé, øïàðãàëêè

Êîììåíòàðèè ê ñòàòüå Êîììåíòàðèè ê ñòàòüå

Îãëàâëåíèå (ðàçâåðíóòü)

ËÅÊÖÈß ¹ 17. Hematopoietic tissue

Hematopoietic tissue is composed of reticular fibers and cells, blood vessels, and sinusoids (thin-walled blood channels). Myeloid, or blood cell-forming tissue, is found in the bone marrow and provides the stem cells that develop into erythrocytes, granulocytes, agranulo-cytes, and platelets. Red marrow is characterized by active hematopo-iesis; yellow bone marrow is inactive and contains mostly fat cells. In the human adult, hematopoiesis takes place in the mar row of the flat bones of the skull, ribs and sternum, the vertebral column, the pelvis, and the proximal ends of some long bones. Erythropoiesis is the process of RBC formation. Bone marrow stem cells (colony-forming units, CFUs) differentiate into proerythroblasts under the influence of the glycoprotein erythropoietin, which is produced by the kidney.

Proerythroblast is a large basophilic cell containing a large spherical euchromatic nucleus with prominent nucleoli.

Basophilic erythroblast is a strongly basophilic cell with nucleus that comprises approximately 75% of its mass. Numerous cytoplasmic polyribosomes, condensed chromatin, no visible nucleoli, and continued hemoglobin synthesis characteristics of this cell.

Polychromatophilic erythroblast is the last cell in this line undergoes mitotic divisions. Its nucleus comprises approximately 50% of its mass and contains condensed chromatin which appears in a "checker-board" pattern. The polychnsia of the cytoplasm is due to the increased quantity of acidophilic hemoglobin combined with the basophilia of cytoplasmic polyribosomes.

Normoblast (orthochromatophilic erythroblast) is a cell with a small heterochromatic nucleus that comprises approximately 25% of its mass. It contains acidophilic cytoplasm because the large amount of hemoglobin and degenerating organelles. The pyknotic nucleus, which is no longer capable of division, is extruded from the cell.

Reticulocyte (polychromatophilic erythrocyte) is an immature aci-dophilic denucleated RBC, which still contains some ribosomes and mitochondria involved in the synthesis of a small quantity of hemoglobin. Approximately 1% of the circulating RBCs are reticulocytes.

Erythrocyte is the mature acidophilic and denucleated RBC. Erythrocytes remain in the circulation approximately 120 days and are then recycled by the spleen, liver, and bone marrow.

Granulopoiesis is the process of granulocyte formation. Bone marrow stem cells differentiate into all three types of granulocytes.

Myeloblast is a cell that has a large spherical nucleus containing delicate euchromatin and several nucleoli. It has a basophilic cytoplasm and no granules. Myeloblasts divide differentiate to form smaller pro-myelocytes.

Promyelocyte is a cell that contains a large spherical indented nucleus with coarse condensed chromatin. The cytoplasm is basophilic and contains peripheral azurophilic granules.

Myelocyte is the last cell in this series capable of division. The nucleus becomes increasingly heterochromatic with subsequent divisions. Specific granules arise from the Golgi apparatus, resulting in neu-trophilic, eosinophilic, and basophilic myelocytes.

Metamyelocyte is a cell whose indented nucleus exhibits lobe formation that is characteristic of the neutrophil, eosinophil, or basophil. The cytoplasm contains azurophilic granules and increasing numbers of specific granules. This cell does not divide. Granulocytes are the definitive cells that enter the blood. Neutrophilic granulocytes exhibit an intermediate stage called the band neutrophil. This is the first cell of this series to appear in the peripheral blood.

It has a nucleus shaped like a curved rod or band.

Bands normally constitute 0,5-2% of peripheral WBCs; they subsequently mature into definitive neutrophils.

Agranulopoiesis is the process of lymphocyte and monocyte for mation. Lymphocytes develop from bone marrow stem cells (lympho-blasts). Cells develop in bone marrow and seed the secondary lympho-id organs (e. g., tonsils, lymph nodes, spleen). Stem cells for T cells come from bone marrow, develop in the thymus and, subsequently, seed the secondary lym phoid organs.

Promonocytes differentiate from bone marrow stem cells (mono-blasts) and multiply to give rise to monocytes.

Monocytes spend only a short period of time in the marrow before being released into the bloodstream.

Monocytes are transported in the blood but are also found in connective tissues, body cavities and organs.

Outside the blood vessel wall, they are transformed into macropha-ges of the mononuclear phagocyte system.

Thrombopoiesis, or the formation of platelets, occurs in the red bone marrow.

Megakaryoblast is a large basophilic cell that contains a U-shaped or ovoid nucleus with prominent nucleoli. It is the last cell that undergoes mitosis.

Megakaryocytes are the largest of bone marrow cells, with diameters of 50 mm or greater. They undergo 4-5 nuclear divi sions without concomitant cytoplasmic division. As a result, the megakaryocyte is a cell with polylobulated, polyploid nucleus and abundant granules in its cytoplasm. As megakaryocyte maturation proceeds, "curtains" of platelet demarcation vesicles form in the cytoplasm. These vesicles coalesce, become tubular, and eventually form platelet demarcation membranes. These membranes fuse to give rise to the membranes of the platelets.

A single megakaryocyte can shed (i. e., produce) up to 3,500 platelets.

New words

reticular - ñåò÷àòûé

sinusoids - ñèíóñîèäû

granulocytes - ãðàíóëîöèòû

agranulocytes - àãðàíóëîöèòû

active - àêòèâíûé

yellow - æåëòûé

glycoprotein - ãëèêîïðîòåèí

erythropoietin - ýðèòðîïîýòèí

large - áîëüøîé

amount - êîëè÷åñòâî

hemoglobin - ãåìîãëîáèí

degenerating - âûðîæäåíèå

capable - ñïîñîáíûé

division - ðàçäåëåíèå

spherical - ñôåðè÷åñêèé

indented - çàçóáðåííûé

condensed - ñæàòûé

chromatin - õðîìàòèí

Çàïîìíèòå ñëåäóþùèå çàñòûâøèå ñëîâîñî÷åòàíèÿ.

to play _ chess to play the piano to play _ football to play the guitar out of _ doors

Çàïîìíèòå, ÷òî ïåðåä îáðàùåíèåì àðòèêëü îïóñêàåòñÿ.

Å. g. What are you doing, _ girls?

Çàïîëíèòå ïðîïóñêè, ãäå íåîáõîäèìî.

1. Do you play... piano?

2. There is... big black piano in our living-room.

3. It is at... wall to... left of... door opposite... sideboard.

4. My mother likes to play. piano.

5. She often plays... piano in... evening.

6..boys like to play... football.

7. What do you do in... evening? - I often play... chess with my grandfather.

8. Where are... children? - Oh, they are out of... doors... weather is fine today.

9. They are playing... badminton in... yard.

10. What... games does your sister like to play?

11. She likes to play... tennis.

12. Do you like to play... guitar?

13. What... colour is your guitar?

14. When we want to write... letter, we take... piece of... paper and... pen.

15. We first write our... ad dress and... date in... right-hand corner.

16. Then on... left-hand side we write... greeting.

17. We must not forget to leave... margin on... left-hand side of... page.

18. On... envelope we write... name and address of... person who will receive it.

19. We stick... stamp on... top of right-hand corner.

20. We posted... letter.

Answer the questions.

1. What is hematopoietic tissue composed of?

2. Where is myeloid found?

3. How is red marrow characterized?

4. What does yellow bone marrow contain?

5. Where does hematopoiesis takes place in the human adult?

6. What is erythropoiesis?

7. What is myeloblast?

8. What is band neutrophil?

9. How long are megakaryocytes?

10. How many platelets can a single megakaryocyte shed?

11. Make the sentences of your own using the new words (10 sentences).

12. Find the definite and indefinite articles in the text.

Àâòîð: Åëåíà Áåëèêîâà

<< Íàçàä: Plasma

>> Âïåðåä: Arteries

Ðåêîìåíäóåì èíòåðåñíûå ñòàòüè ðàçäåëà Êîíñïåêòû ëåêöèé, øïàðãàëêè:

Êëèíè÷åñêàÿ ïñèõîëîãèÿ. Øïàðãàëêà

Ïñèõîëîãèÿ. Êîíñïåêò ëåêöèé

Âîçðàñòíàÿ ïñèõîëîãèÿ. Êîíñïåêò ëåêöèé

Ñìîòðèòå äðóãèå ñòàòüè ðàçäåëà Êîíñïåêòû ëåêöèé, øïàðãàëêè.

×èòàéòå è ïèøèòå ïîëåçíûå êîììåíòàðèè ê ýòîé ñòàòüå.

<< Íàçàä

Ïîñëåäíèå íîâîñòè íàóêè è òåõíèêè, íîâèíêè ýëåêòðîíèêè:

Áîëüøîé àäðîííûé êîëëàéäåð ïðåêðàùàåò ðàáîòó 16.01.2026

Ôèçèêà ýëåìåíòàðíûõ ÷àñòèö - îäíà èç ñàìûõ ïåðåäîâûõ îáëàñòåé íàóêè, ãäå êàæäûé ýêñïåðèìåíò ìîæåò èçìåíèòü íàøå ïîíèìàíèå ìèðîçäàíèÿ. Öåíòðàëüíûì èíñòðóìåíòîì ýòèõ èññëåäîâàíèé ÿâëÿåòñÿ Áîëüøîé àäðîííûé êîëëàéäåð (LHC), óíèêàëüíûé óñêîðèòåëü ÷àñòèö, ïîçâîëÿþùèé èçó÷àòü ñàìûå ôóíäàìåíòàëüíûå çàêîíû ïðèðîäû. Íåäàâíî ñòàëî èçâåñòíî, ÷òî LHC âðåìåííî ïðåêðàùàåò ñâîþ ðàáîòó äëÿ ìàñøòàáíîé ìîäåðíèçàöèè, êîòîðàÿ ïîäãîòîâèò åãî ê íîâîìó ýòàïó ýêñïåðèìåíòîâ ñ ãîðàçäî áîëüøåé ïðîèçâîäèòåëüíîñòüþ. Êîëëàéäåð, ðàñïîëîæåííûé â ïîäçåìíîì òîííåëå âäîëü øâåéöàðñêî-ôðàíöóçñêîé ãðàíèöû, ñîçäàåò ñòîëêíîâåíèÿ ÷àñòèö íà íåâåðîÿòíî âûñîêèõ ýíåðãèÿõ. Èìåííî çäåñü â 2012 ãîäó ó÷åíûå îòêðûëè áîçîí Õèããñà - êëþ÷åâóþ ÷àñòèöó, îáúÿñíÿþùóþ, ïî÷åìó äðóãèå ýëåìåíòàðíûå ÷àñòèöû èìåþò ìàññó. Ýòî îòêðûòèå ñòàëî îäíèì èç ñàìûõ çíà÷èìûõ ñîáûòèé ñîâðåìåííîé ôèçèêè è ïîäòâåðäèëî ïðåäñêàçàíèÿ Ñòàíäàðòíîé ìîäåëè. Ïðè÷èíîé âðåìåííîé îñòàíîâêè LHC ñòàëî ðàçâåðòûâàíèå ïðîåêòà High-Luminosity LHC (HL-LHC). Ìîäåðíèçàöèÿ ïîçâ ...>>

Ðîáîò-áàðìåí AI Barmen 16.01.2026

Àìåðèêàíñêèå èíæåíåðû ñîçäàëè AI Barmen - ðîáîòà-áàðìåíà, ñïîñîáíîãî íå òîëüêî ãîòîâèòü êîêòåéëè, íî è çàïîìèíàòü ïðåäïî÷òåíèÿ ãîñòåé. AI Barmen ïðåäñòàâëÿåò ñîáîé àâòîíîìíóþ ñèñòåìó, êîòîðóþ ìîæíî óñòàíàâëèâàòü ïðàêòè÷åñêè â ëþáûõ ìåñòàõ - îò áàðîâ è ðåñòîðàíîâ äî ãîñòèíèö, àýðîïîðòîâ è êîðïîðàòèâíûõ ìåðîïðèÿòèé. Ðîáîò ñî÷åòàåò ìåõàíè÷åñêèé ìàíèïóëÿòîð ñ èíòåëëåêòóàëüíîé ïðîãðàììîé, êîòîðàÿ ïîäáèðàåò íàïèòêè íà îñíîâå èñòîðèè çàêàçîâ êîíêðåòíîãî ïîëüçîâàòåëÿ. Ãîñòè ìîãóò îñòàâàòüñÿ àíîíèìíûìè èëè ðàçðåøèòü ñèñòåìå çàïîìèíàòü èõ âêóñû, ÷òî ïîçâîëÿåò ïîëó÷àòü îäèíàêîâî êà÷åñòâåííûé ïåðñîíàëèçèðîâàííûé êîêòåéëü â ëþáîé òî÷êå, ãäå óñòàíîâëåí AI Barmen. Ðîáîò ãîòîâèò øèðîêèé ñïåêòð êîêòåéëåé ñ âûñîêîé òî÷íîñòüþ, êîíòðîëèðóåò çàïàñû èíãðåäèåíòîâ è àâòîìàòè÷åñêè âåäåò ó÷åò, ÷òî ñíèæàåò çàòðàòû è ìèíèìèçèðóåò îøèáêè. Äëÿ ðàáîòû óñòðîéñòâà äîñòàòî÷íî ñòàíäàðòíîé ðîçåòêè, ïîäêëþ÷åíèå ê âîäå íå òðåáóåòñÿ, ÷òî äåëàåò åãî ìîáèëüíûì è óäîáíûì äëÿ ýêñïëóàòàöèè â ñàìûõ ðàçíûõ óñëîâèÿõ. Ñèñòå ...>>

Ñòåðèëüíîãî íåéòðèíî íå ñóùåñòâóåò 15.01.2026

 ôèçèêå ýëåìåíòàðíûõ ÷àñòèö ïîèñê íîâûõ, ïîêà íå îáíàðóæåííûõ îáúåêòîâ èãðàåò êëþ÷åâóþ ðîëü â ïîíèìàíèè óñòðîéñòâà Âñåëåííîé. Èíîãäà òàêèå ïîèñêè ïðèâîäÿò ê ãðîìêèì îòêðûòèÿì, à èíîãäà - ê íå ìåíåå âàæíûì îòðèöàòåëüíûì ðåçóëüòàòàì, êîòîðûå ïîçâîëÿþò îòáðîñèòü íåâåðíûå íàïðàâëåíèÿ. Èìåííî ê òàêèì ñëó÷àÿì îòíîñèòñÿ íåäàâíèé âûâîä ó÷åíûõ î ñóäüáå ñòåðèëüíîãî íåéòðèíî - îäíîé èç ñàìûõ èíòðèãóþùèõ ãèïîòåòè÷åñêèõ ÷àñòèö ïîñëåäíèõ äåñÿòèëåòèé. Èññëåäîâàòåëè èç àìåðèêàíñêîé ëàáîðàòîðèè Fermilab îôèöèàëüíî ñîîáùèëè, ÷òî èì íå óäàëîñü íàéòè äîêàçàòåëüñòâà ñóùåñòâîâàíèÿ ñòåðèëüíîãî íåéòðèíî. Ê òàêîìó âûâîäó ïðèøëà êîìàíäà ýêñïåðèìåíòà MicroBooNE ïîñëå ìíîãîëåòíåãî àíàëèçà ñòîëêíîâåíèé íåéòðèíî, êîòîðûå ðàíåå ðàññìàòðèâàëèñü êàê âîçìîæíûé íàìåê íà ñóùåñòâîâàíèå ÷åòâåðòîãî òèïà ýòèõ ÷àñòèö. Ïðåäïîëàãàëîñü, ÷òî ñòåðèëüíîå íåéòðèíî âçàèìîäåéñòâóåò ñ ìàòåðèåé èñêëþ÷èòåëüíî ÷åðåç ãðàâèòàöèþ, ÷òî äåëàëî åãî êðàéíå òðóäíûì îáúåêòîì äëÿ îáíàðóæåíèÿ.  ðàìêàõ ñîâðåìåííîé ôèçèêè íåéòðèíî èçâåñòíû â ò ...>>

Ñëó÷àéíàÿ íîâîñòü èç Àðõèâà

Ãåííîå îìîëîæåíèå 30.04.2016

Ýëèçàáåò Ïýððèø, ðóêîâîäèòåëü àìåðèêàíñêîé íàó÷íî-èññëåäîâàòåëüñêîé êîìïàíèè BioViva, ñòàëà ïåðâûì ÷åëîâåêîì, íà êîòîðîì áûëà óñïåøíî èñïûòàíà îìîëàæèâàþùàÿ ãåííàÿ òåðàïèÿ.

Íåñìîòðÿ íà òî, ÷òî ïåðâûå âîçðàñòíûå èçìåíåíèÿ ìû îòìå÷àåì ïî âíåøíèì ïðèçíàêàì, ïðîöåññû ñòàðåíèÿ ôîðìèðóþòñÿ è ðàçâèâàþòñÿ âíóòðè - íà êëåòî÷íîì óðîâíå. Êîíöåâûå ó÷àñòêè õðîìîñîì íàçûâàþò òåëîìåðàìè. Îíè íå íåñóò ãåíåòè÷åñêîé èíôîðìàöèè, íî çàùèùàþò õðîìîñîìû, âûïîëíÿÿ ðîëü ñâîåîáðàçíîãî "áóôåðà" ïðîòèâ èçíîñà. Îäíàêî êàæäûé ðàç, êîãäà äåëèòñÿ êëåòêà, òåëîìåðû ïîñòåïåííî óìåíüøàþòñÿ, ïîêà íå ñòàíóò íàñòîëüêî êîðîòêèìè, ÷òî áîëüøå íå ìîãóò çàùèùàòü õðîìîñîìû. Êàê ðåçóëüòàò, êëåòêà ñòàðååò è áîëüøå íå ìîæåò âûïîëíÿòü ñâîè ôóíêöèè.

Ôåðìåíò ïîä íàçâàíèåì òåëîìåðàçà ñïîñîáåí äîñòðàèâàòü êîðîòêèå òåëîìåðû. Ñòàðåþùèå êëåòêè îðãàíèçìà áëàãîäàðÿ òåëîìåðàçå ñíîâà ïðèîáðåòàþò ñïîñîáíîñòü äåëèòüñÿ, ïîäîáíî ìîëîäûì è çäîðîâûì êëåòêàì. Äî ñèõ ïîð ìåòîäèêà óäëèíåíèÿ òåëîìåð èñïûòûâàëàñü ëèøü íà êóëüòóðàõ âûðàùåííûõ êëåòîê è ëàáîðàòîðíûõ æèâîòíûõ.

Ïåðâûé ýêñïåðèìåíò ïî èñïûòàíèþ óíèêàëüíîé ìåòîäèêè îìîëîæåíèÿ íà ÷åëîâåêå ñòàðòîâàë â ñåíòÿáðå 2015 ãîäà, êîãäà 44-ëåòíÿÿ Ýëèçàáåò ðåøèëàñü ïðîéòè äâà ýêñïåðèìåíòàëüíûõ êóðñà ãåííîé òåðàïèè, ðàçðàáîòàííûõ åå ñîòðóäíèêàìè äëÿ çàìåäëåíèÿ ñòàðåíèÿ. Ïåðâûé êóðñ ïðåäíàçíà÷åí äëÿ ïðåäîòâðàùåíèÿ ïîòåðü ìûøå÷íîé ìàññû ñ âîçðàñòîì, à âòîðîé íàïðàâëåí íà óâåëè÷åíèå âûðàáîòêè òåëîìåðàçû. Èíúåêöèè áûëè ñäåëàíû Ýëèçàáåò â Êîëóìáèè, òàê êàê ïðåïàðàòû íå îäîáðåíû Óïðàâëåíèåì ïî ñàíèòàðíîìó íàäçîðó çà êà÷åñòâîì ïèùåâûõ ïðîäóêòîâ è ìåäèêàìåíòîâ ÑØÀ (FDA).

Òåïåðü ñòàëè èçâåñòíû ïåðâûå ðåçóëüòàòû ãåííîé òåðàïèè - è îíè îøåëîìëÿþò! Àíàëèçû ïîêàçàëè, ÷òî ïðåïàðàòû äåéñòâèòåëüíî îñòàíîâèëè óêîðà÷èâàíèå òåëîìåð. Ëåéêîöèòû â êðîâè Ïýððèø ñòàëè áèîëîãè÷åñêè ìîëîæå, à òåëîìåðû "óäëèíèëèñü" íà 20 ëåò. Îòêðûòèå êîìïàíèè BioViva ïðèâëåêëî âíèìàíèå êàê ó÷åíûõ, òàê è èíâåñòîðîâ, à ýêñïåðèìåíò òåì âðåìåíåì ïðîäîëæàåòñÿ è èññëåäîâàòåëè òùàòåëüíî ñëåäÿò çà çäîðîâüåì Ïýððèø.

Äðóãèå èíòåðåñíûå íîâîñòè:

▪ Ýêøåí-êàìåðà Amkov AMK100S

▪ Ïðåäñêàçàíèå ìîëíèè

▪ Ðàçðàáîòàíà ñïåöèôèêàöèÿ USB4

▪ Àíàëîãîâûé îïåðàöèîííûé óñèëèòåëü èç 2D-òðàíçèñòîðîâ

▪ Àêêóìóëÿòîðû èç èñïîëüçîâàííîé ñòåêëÿííîé òàðû

Ëåíòà íîâîñòåé íàóêè è òåõíèêè, íîâèíîê ýëåêòðîíèêè

 

Èíòåðåñíûå ìàòåðèàëû Áåñïëàòíîé òåõíè÷åñêîé áèáëèîòåêè:

▪ ðàçäåë ñàéòà Ýëåêòðèê â äîìå. Ïîäáîðêà ñòàòåé

▪ ñòàòüÿ  âàííîé êîìíàòå - èãðóøêà âìåñòî ñòàêàí÷èêà. Ñîâåòû äîìàøíåìó ìàñòåðó

▪ ñòàòüÿ ×òî òàêîå âîçäóõ? Ïîäðîáíûé îòâåò

▪ ñòàòüÿ Ñàíèòàðíûå íîðìû è ïðàâèëà (ÑàíÏèÍ, ÑÏ). Ñïðàâî÷íèê/a>

▪ ñòàòüÿ Ðÿæåíêà. Ïðîñòûå ðåöåïòû è ñîâåòû

▪ ñòàòüÿ Âîñïëàìåíÿþùàÿ âîäà. Ñåêðåò ôîêóñà

Îñòàâüòå ñâîé êîììåíòàðèé ê ýòîé ñòàòüå:

Èìÿ:


E-mail (íå îáÿçàòåëüíî):


Êîììåíòàðèé:





Ãëàâíàÿ ñòðàíèöà | Áèáëèîòåêà | Ñòàòüè | Êàðòà ñàéòà | Îòçûâû î ñàéòå

www.diagram.com.ua

www.diagram.com.ua
2000-2026